Balance Sheet
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

Goldenwell Biotech (GWLL) Enterprise Value (2019 - 2025)

Goldenwell Biotech's Enterprise Value history spans 7 years, with the latest figure at -$45622.0 for Q3 2025.

  • For Q3 2025, Enterprise Value fell 859.45% year-over-year to -$45622.0; the TTM value through Sep 2025 reached -$45622.0, down 859.45%, while the annual FY2024 figure was -$49404.0, 7.19% up from the prior year.
  • Enterprise Value reached -$45622.0 in Q3 2025 per GWLL's latest filing, up from -$76507.0 in the prior quarter.
  • In the past five years, Enterprise Value ranged from a high of -$4755.0 in Q3 2024 to a low of -$248569.0 in Q1 2021.
  • Average Enterprise Value over 5 years is -$87931.7, with a median of -$45996.0 recorded in 2022.
  • Peak YoY movement for Enterprise Value: skyrocketed 82.54% in 2022, then plummeted 859.45% in 2025.
  • A 5-year view of Enterprise Value shows it stood at -$213556.0 in 2021, then soared by 78.46% to -$45996.0 in 2022, then fell by 15.73% to -$53231.0 in 2023, then rose by 7.19% to -$49404.0 in 2024, then increased by 7.66% to -$45622.0 in 2025.
  • Per Business Quant, the three most recent readings for GWLL's Enterprise Value are -$45622.0 (Q3 2025), -$76507.0 (Q2 2025), and -$17127.0 (Q1 2025).